logo
Plus   Neg
Share
Email

Thomson Reuters Slashes FY20 Revenue Growth Outlook Amid COVID-19 - Quick Facts

While reporting financial results for the first quarter on Tuesday, Thomson Reuters Corp. (TRI,TRI.TO) slashed its revenue and organic revenue growth guidance for the full-year 2020, to reflect its currently estimated impact of the COVID-19 pandemic. It also provided revenue growth outlook for the second quarter.

For fiscal 2020, the company now projects total revenue growth of 1 to 2 percent and organic revenue growth of flat to 1 percent.

Previously, the company expected total revenue growth of 4.5 to 5.5 percent and organic revenue growth of 4 to 4.5 percent.

For the second quarter, the company expects total company revenues to decline 1 to 2 percent and organic revenues to decline 2 to 3 percent, primarily due to cancellations of events in the Reuters News business and delays in shipping of certain Global Print materials.

On average, analysts polled by Thomson Reuters expect the company to report revenue growth of 3.3 percent to $2.87 billion for the quarter and revenue growth of 3.0 percent to $11.67 billion for the year.

The updated outlook assumes diminished economic activity through the second quarter followed by a gradual recovery through the second half of 2020. It also assumes that the company will be able to mitigate the impact of anticipated lower 2020 revenues through its $100 million cost reduction program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT